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Genital human papillomavirus (HPV) infection 
is the most common sexually transmitted viral 
disease in the world.[1,2] HPV infection of the genital 
epithelium is associated with a range of diseases, 
including genital warts and cancers of the cervix, 
vagina, vulva, anus and penis and their precursors. However, 
HPV infection may exist in the latent form in apparently normal 
epithelium.[3,4] Genital warts are typically associated with low-risk 
HPV genotypes, most commonly HPV types 6 and 11.[5] However, 
recent studies have shown that 20 - 50% of genital warts may be 
co-infected with high-risk HPV types associated with malignancy.[6,7]
Although genital warts are not life-threatening, they cause 
significant psychosocial harm, including low self-esteem, negative 
self-perception, embarrassment and anxiety.[8,9] Genital warts 
represent a health problem for the individual, and carry a significant 
economic burden for society owing to their generally poor response 
to conventional therapies and the need for multiple therapeutic 
interventions.[9] Immunisation against high-risk HPV types to prevent 
cervical cancers is likely to have a positive public health impact in the 
future. In addition, the quadrivalent vaccine, which has been approved 
for use in males and females aged 9 - 26 years, protects against the HPV 
types that cause 90% of genital warts (i.e. types 6 and 11).[4]
Genital warts are a common reason for referral to the Colposcopy 
Clinic at Groote Schuur Hospital (GSH), a tertiary hospital serving 
the Cape Town area and the Western Cape Province, South Africa. 
We undertook this study to examine the nature of the disease, seek-
ing particularly to determine the rate of recurrence after treatment, 
the response to various therapies using trichloroacetic acid (TCA), 
electrocautery and carbon dioxide laser, and the HPV genotypes 
associated with genital warts in women referred to our clinic.
Objectives
To describe the demographic features of women diagnosed with 
genital warts, the characteristics of genital warts seen and treatment 
modalities used, and to determine the type of HPV infections 
associated with warts according to HIV status and response to 
treatment at 3 months.
Methods
Study design
This was a prospective observational study performed over a 
6-month period (1 April - 30 September 2010). Subjects were 
recruited from women diagnosed with genital warts referred to the 
Colposcopy Clinic at GSH. Those who were pregnant or unable to 
undergo gynaecological examination were excluded.
Written informed consent was obtained from all participants in 
their home language (English, Afrikaans or Xhosa), with subsequent 
back-translation to ensure accuracy. Approval for the study was 
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obtained from the Human Research Ethics Committee of the 
University of Cape Town and the GSH Bioethics Unit. Separate 
consent was sought for photographing the warts.
At enrolment, each participant was interviewed using a 
structured questionnaire. A urine pregnancy test was performed 
prior to clinical examination if the patient had been amenorrhoeic 
for more than a month and/or was not using contraception. All 
participants had a detailed examination of the anogenital area, and 
a macroscopic photograph of the lesions was taken. Cervical and 
anal smears were taken during colposcopy, which was followed by 
detailed examination of the cervix, vagina, vulva and anus. Any 
acetowhite areas observed during colposcopy of the cervix and 
any macroscopically visible anogenital warts were biopsied for 
histological investigation. The anal smears were not examined for 
this study. All patients received serological screening for HIV and 
syphilis. Those confirmed as HIV-positive had CD4 cell counts and 
HIV viral load determined in accordance with HIV management 
guidelines at the time of the study.
HPV analysis
HPV DNA analysis was performed at the Institute of Infectious 
Disease and Molecular Medicine, University of Cape Town. All 
biopsy specimens for HPV DNA analysis were given a unique 
identification number that was matched to the participant’s data and 
was only known to the principal investigator. The specimens were 
each placed in a separate container with the specific identification 
number and collected by the testing laboratory on a daily basis. When 
the sample was appropriately sized, the Qiagen DNA extraction 
mini-kit (cat. 51304) was used to complete extraction. For biopsy 
samples in excess of the recommended size, the Qiagen protocol was 
used only to provide a first-step digestion lysate of tissue. Anogenital 
wart biopsy DNA was subjected to HPV typing employing the Roche 
Linear Array HPV genotyping kit (testing for HPV types 11, 16, 18, 
26, 31, 33, 35, 39, 40, 45, 51, 52, 53, 54, 55, 58, 59, 61, 62, 66, 68, 70, 72, 
73, 81, 82, 83, 84 and 89) according to the manufacturer’s instructions 
(Roche Molecular Systems, USA).
The HPV target DNA for amplification was a 450-bp fragment of 
the L1 region. To confirm sample quality and the DNA extraction 
process, a second target was a 268-bp fragment of the human β-globin 
gene. A sample was considered adequate if it was β-globin-positive 
(internal control) or β-globin-negative but HPV DNA-positive.
Pathology
Cervical cytology and biopsy specimens for histological confirmation 
were interpreted by pathologists at the GSH pathology laboratory. 
The pathologists examining the specimens were not blinded as to the 
HIV status of the participants.
Treatment modalities
All participants received treatment based on the morphology and 
distribution of lesions. The lesions were classified as small, moderate, 
and large or extensive. Small lesions referred to multiple small 
warts around the genitalia of diameter <0.5 cm, moderate lesions to 
warts with diameter 0.5 - 1.0 cm, and large or extensive lesions to a 
perineum infiltrated by warts.
Treatments involved topical application of TCA; electrocautery or 
excision under local or general anaesthesia; or ablation with a CO2 
laser under general anaesthesia, depending on the size of the warts. 
Women with small warts received topical treatment with TCA and 
were advised to attend weekly until no visible lesions were seen. 
Women with warts of moderate size were treated with electrocautery 
under local anaesthesia in the clinic setting. Women requiring 
general anaesthesia for excision of large or extensive warts or CO2 
laser were given a date for admission to the ward for laser ablation 
and surgery.
All patients were seen after treatment for follow-up assessment 
of their response. The wart(s) were categorised as recurrent if 
recurring 3 months after treatment, or persistent if recurring less 
than 3 months after treatment. Patients who were found to be 
HIV-positive were referred to a social welfare officer for post-test 
counselling and subsequently referred for management at their 
local HIV clinic for initiation of antiretroviral treatment (according 
to the 2010 Clinical Guidelines on the Management of HIV and AIDS 
in Adults and Adolescents of the National Department of Health, 
SA[10]).
Data collection and statistical analysis
To guarantee confidentiality, all participants were allocated a unique 
study number. Data obtained were entered into an anonymous 
database and data analysis was performed using SPSS Statistical 
Software, version 19.
Ethical considerations
Ethical approval was obtained from the Research Ethics Committee 
of the Faculty of Health Sciences, University of Cape Town (Ref. 
131/2010).
Results
A total of 156 patients (mean age 27 years, range 15 - 53) partici-
pated in the study. Ninety-four patients (60.3%) were new cases, 
40 (25.6%) were recurrent cases and 22 (14.1%) had been treated 
previously but had persistent disease. Table 1 summarises the 
demographic and clinical characteristics of the participants. More 
than 50% of the women were single (not legally married) but 
sexually active. The majority (n=128, 82.1%) had had their first 
sexual encounter before the age of 20 years, often between the ages 
of 15 and 19.
The majority of the women (123/156, 78.8%) were HIV-positive 
(Table 1). Four patients declined HIV screening and were categorised 
as ‘HIV status unknown’. Of the HIV-positive women, 83/123 (67.5%) 
were already on antiretroviral therapy with a median CD4 count of 
356 cells/µL (range 22 - 483).
Table 2 shows the modalities of treatment administered. Local 
ablation with TCA and electrocautery under local anaesthesia were 
performed on patients with lesions of small to moderate size. Patients 
with large and extensive lesions received CO2 laser. The average 
length of hospital stay for these patients was 5.1 days (range 1 - 7) 
owing to poor home circumstances and requirement for wound care. 
Histological examination confirmed genital warts in 154 patients. 
Two of the 156 specimens (1.3%) were reported as invasive squamous 
cell carcinoma, and these patients were treated with radical wide 
local excision of the lesions and groin node dissection. Both were 
HIV-positive.
One hundred and thirteen of the 156 specimens were 
successfully investigated for HPV with positive β-globin tests. 
Of these 113 specimens, 7 (6.2%) had no detectable HPV DNA. 
Table 3 shows the relationship between HPV DNA detection and 
HIV status. Of 106 HPV DNA-positive patients, 85 (80.2%) were 
HIV-positive.
Table 4 shows the association between HPV DNA status and 
cervical cytological abnormalities. Seventy of 106 HPV DNA-
positive women (66.0%) had cervical cytological abnormalities 
noted: high-grade squamous intraepithelial lesions (HSILs) in 8.5% 
(9/106) and low-grade squamous intraepithelial lesions (LSILs) in 
RESEARCH
681       August 2015, Vol. 105, No. 8
52.8% (56/107). Thirty-six of 106 patients 
with HPV DNA-positive warts (34.0%) 
had normal cervical cytological findings. 
Women with cervical abnormalities 
were subsequently recalled and managed 
according to standard clinical protocols.
Of the 7 women with no HPV DNA 
detectable from biopsied genital warts, 2 had 
LSILs, 4 had normal cytological findings, 
and 1 had no cervical cytology performed 
(virgo intacta).
Table 5 shows the HPV genotypes detected 
from anogenital warts. The ten most frequent 
types detected were HPV 11, 6, 89, 61, 55, 62, 
81, 16, 18 and 45. HPV genotypes 6 and 11 were 
the most common genotypes encountered in 
both HIV-positive and negative women. In 
addition to the most prevalent genotypes 6 
and 11, HIV-positive cases yielded types 16, 18, 
31, 33, 35, 39, 40, 45, 51, 52, 53, 54, 55, 58, 59, 
61, 62, 66, 68, 70, 72, 73, 81, 82, 83, 84 and 89. 
Fifteen of 85 HIV-positive women who were 
HPV DNA-positive (17.6%) were co-infected 
with HPV 16 and 18, among other types.
Table 1. Demographic features and clinical parameters of study participants*
Demographics/clinical parameters
New
(N=94)
n (%)
Recurrent
(N=40)
n (%)
Persistent
(N=22)
n (%)
Total 
(N=156)
n (%) p-value
Marital status 0.118
Single, not sexually active 19 (63.3) 6 (20.0) 5 (16.7) 30
Single, sexually active 56 (60.9) 27 (29.3) 9 (9.8) 92
Married 13 (62.0) 4 (19.9) 4 (19.0) 21
Separated/divorced/widow 6 (46.2) 3 (23.0) 4 (30.8) 13
Age at first sexual exposure (years) 0.184
≤14 9 (75.0) 2 (16.7) 1 (8.3) 12
15 - 19 69 (59.5) 33 (28.4) 14 (12.1) 116
≥20 16 (59.3) 5 (18.5) 6 (22.2) 27
Virgo intacta - - 1 (100.0) 1
Level of education 0.034
Primary 13 (81.3) - 4 (18.7) 16
Secondary 67 (57.8) 36 (31.0) 13 (11.2) 116
Tertiary 14 (58.3) 4 (16.7) 6 (25.0) 24
Smoking 0.579
Yes 9 (56.3) 3 (18.8) 4 (24.9) 16
No 77 (61.1) 34 (27.0) 15 (11.9) 126
Previously 8 (57.2) 3 (21.4) 3 (21.4) 14
Alcohol consumption 0.273
Yes 13 (54.2) 5 (20.8) 6 (25.0) 24
No 76 (60.3) 35 (27.8) 15 (11.9) 126
Previously 5 (83.3) - 1 (16.7) 6
Use of drugs/snuff 0.836
Yes 1 (100.0) - - 1
No 92 (60.1) 39 (25.5) 22 (14.4) 153
Previously 1 (50.0) 1 (50.0) - 2
HIV status 0.305
Positive 71 (57.7) 36 (29.3) 16 (13.20 123
Negative 21 (72.4) 3 (10.3) 5 (17.3) 29
Unknown 2 (50.0) 1 (25.0) 1 (25.0) 4
*Other than level of education (p=0.034), there were no significant associations between marital status, age at first sexual exposure, smoking, alcohol consumption, use of drugs/snuff and HIV 
status, and new, recurrent or persistent disease.
Table 2. Treatment modalities administered
Treatment
New
(N=94)
n (%)
Recurrent
(N=40)
n (%)
Persistent
(N=22)
n (%)
Total 
(N=156)
n (%)
Local ablation with TCA 7 (63.6) 2 (18.2) 2 (18.2) 11 (7.1)
Electrocautery under LA 68 (62.4) 28 (25.7) 13 (11.9) 109 (69.9)
Electrocautery/CO2 laser under GA 17 (51.5) 9 (27.3) 7 (21.2) 33 (21.2)
LA = local anaesthesia; GA = general anaesthesia.
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Of the 106 women who were positive for 
HPV DNA, 58 (54.7%) had a single genotype 
identified. Co-infection with more than one 
genotype was detected in 43/85 HIV-positive 
women (50.6%) as opposed to 3/18 HIV-
negative women (16.7%). This difference 
was statistically not significant (p=0.771), 
possibly owing to the small number of HIV-
negative cases. Among the HIV-positive 
cases, 15 genotypes were detected from one 
patient and 11 genotypes from two patients. 
The maximum number of HPV genotypes 
detected from HIV-negative women was 
three, detected in two specimens. One 
of the two specimens with histological 
confirmation of invasive squamous cell 
carcinoma was available for HPV typing and 
had seven HPV types detected (HPV 11, 16, 
53, 55, 61, 62 and 89).
 Fifty-three of 113 women for whom 
HPV analysis could be performed (46.9%) 
returned for follow-up 3 months after 
treatment. Of this group, 35 (66.0%) 
were HIV- and HPV DNA-positive and 
13 (24.5%) were HIV-negative but HPV 
DNA-positive (Table 6). The majority of 
recurrences at 3 months’ follow-up were 
in HIV-positive women (26/30, 86.7%). In 
the HIV- and HPV DNA-positive group, 25 
women (71.4%) had recurrent genital warts 
compared with three women (23.1%) in 
the HIV-negative, HPV DNA-positive group 
(p=0.114). Recurrent genital warts were 
seen more often in women with more than 
one HPV genotype initially detected (40%, 
10/40) than in those with a single detectable 
genotype (60%, 15/25) (p=0.172).
The most common HPV types detected 
were HPV 11 (54.7%, 58/106) and HPV 6 
(39.6%, 42/106). Three women had dual 
HPV 6 and HPV 11 infection. Of note, 
39/106 (36.8%) of women were infected with 
high-risk HPV types such as 16, 18, 31, 33, 
35, 39, 45 and 51. Only nine women (8.5%) 
had no infection with either HPV 6 or 11.
Discussion
It is well known that persistent infection 
with HPV is a necessary precursor for the 
development of cervical cancer. Infection 
with HPV is also associated with genital 
warts and other types of anogenital neoplasia, 
including penile, anal and oropharyngeal 
tumours.[11] Although genital warts are 
not life threatening, they are common and 
cause considerable psychosocial and sexual 
morbidity.[9] Genital warts in both men and 
women are readily transmitted, have a high 
recurrence rate after treatment, and cause 
local pain and discomfort.[9,12] Treatment for 
genital warts also requires multiple clinical 
visits associated with increased cost. In the 
Table 3. HPV DNA detection in genital warts according to HIV status*
HPV DNA
HIV-positive
(N=90)
n (%)
HIV-negative
(N=20)
n (%)
HIV status unknown
(N=3)
n (%)
Total
(N=113)
n (%)
HPV DNA-positive 85 (80.2) 18 (17.0) 3 (2.8) 106 (93.8)
HPV DNA-negative 5 (71.4) 2 (28.6) - 7 (6.2)
*p=0.684 (statistically not significant).
Table 4. Correlation of HPV DNA detection with cervical cytological findings
Cytological results
HPV DNA-positive
(N=106)
n (%)
HPV DNA-negative
(N=6)
n (%)
Total
(N=112)*
n (%)
Normal 36 (34.0) 4 (66.7) 40 (35.7)
LSIL 56 (52.8) 2 (33.3) 58 (51.8)
HSIL 9 (8.5) - 9 (8.0)
ASCUS 5 (4.7) - 5 (4.5)
ASCUS = atypical squamous cell of undetermined significance.
*Number of Pap smears was 112 because one patient was virgo intacta and did not have a Pap smear performed.
Table 5. HPV genotypes identified in genital warts
Commonest HPV  
genotypes isolated
HIV-positive
(N=85)
n (%)
HIV-negative
(N=21)
n (%)
Total
(N=106)*
n (%)
11 46 (82.1) 10 (17.9) 56
6 32 (78.0) 9 (18.0) 41
89 19 (100.0) - 19
61 16 (94.1) 1 (5.9) 17
55 12 (100.0) - 12
62 12 (100.0) - 12
81 9 (90.0) 1 (10.0) 10
16 8 (100.0) - 8
18 8 (100.0) - 8
45 8 (100.0) - 8
53 8 (100.0) - 8
83 8 (100.0) - 8
66 6 (100.0) - 6
51 5 (100.0) - 5
52 5 (100.0) - 5
58 5 (100.0) - 5
59 5 (100.0) - 5
72 5 (100.0) - 5
39 4 (100.0) - 4
68 4 (100.0) - 4
40 3 (100.0) - 3
73 3 (100.0) - 3
31 2 (100.0) - 2
33 2 (100.0) - 2
84 2 (100.0) - 2
Continued ...
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USA, the cost was highest in young adults 
(USD 1 717/1 000 person-years) for women 
aged 15 - 24 years.[13]
Main findings
In this study, the mean age of the patients 
recruited was 27 years; 63 (40.4%) were 
aged ≤25. This is consistent with the known 
prevalence of HPV infection, which peaks 
at age 15 - 25 years.[4] A number of studies 
show that the occurrence of genital warts 
is strongly linked with sexual behaviour, 
and more weakly associated with cigarette 
smoking.[14] More than 80% of patients in this 
study were sexually active, and 80.1% had 
had more than one sexual partner. However, 
only 19.2% were current or ex-smokers. It 
has been postulated that cigarette smoking 
is associated with more risky sexual 
behaviours, and biologically with decreased 
S-100 and CD1a-positive Langerhans cells in 
the cervical epithelium. [14]
It is well known that HIV infection is 
an important risk factor for HPV infection 
and persistence. HIV-seropositive women 
are at increased risk of contracting HPV 
infection and developing HPV-related 
preinvasive and invasive lesions compared 
with their seronegative counterparts.[3,4] In 
addition, HIV-seropositive women have a 
high rate of persistent HPV infection with 
high-risk HPV genotypes (16 and 18),[5] 
which are responsible for 70% of cervical 
cancers.
In this study, the majority of the patients 
(n=123, 78.9%) were HIV-positive. HIV 
seropositivity and HIV-induced immune 
suppression are known to be associated 
with an increased prevalence of anogenital 
HPV infections in men and women. This 
association involves HPV infection of all 
types, as well as infections with multiple 
types of HPV, including the oncogenic 
types.[15] Our study showed that HIV-
infected women not only had genital 
warts with more HPV genotypes, with the 
maximum number being 15 in one patient, 
but also had multiple oncogenic types of 
HPV. HPV types 6 and 11 were detected 
in most cases (85.8%). The role of the 
other HPV types in the pathogenesis of 
genital warts is unknown. It is also not clear 
what the implications are in terms of HPV 
vaccination, as this raises the question as 
to whether the other types will also cause 
genital warts.
Study strengths and limitations
The strength of this study is that it was 
conducted prospectively, with detailed 
documentation of the clinical diagnosis of 
genital warts by one clinician. Limitations 
include the short follow-up period of only 
3 months, with a significant number of 
patients lost to follow-up. Furthermore, 
these data refer to a group of women referred 
specifically for genital warts and cannot 
be considered to be representative of the 
general population.
Interpretation
Our data show that HIV-infected women 
have a high incidence of HPV infection 
and infection with multiple types of 
HPV, including high-risk types. Recently, 
some investigators have suggested that 
HPV infection is a risk factor for HIV 
transmission. Lissouba et al.,[16] in their 
systematic review and meta-analysis of 
2 601 abstracts, six observational studies 
and 6 567 participants, found that HIV 
acquisition was significantly associated 
with HPV infection (summary odds 
ratio (OR) 1.96; 95% confidence interval 
(CI)  1.55 - 2.49). HIV incident infection 
was significantly associated with high-risk 
HPV in five of six studies and with low-risk 
HPV in two out of five. The association was 
significant for high-risk HPV (summary 
OR 1.92; 95% CI 1.49 - 2.46) and borderline 
for low-risk HPV. However, our study was 
not designed to evaluate the impact of 
HPV infection on HIV transmission. This 
study showed that HIV co-infection is a 
risk factor for infection with multiple HPV 
genotypes.
Conclusions
There was a high rate of HIV positivity 
among women with genital warts recruited 
into the study. HPV-associated disease is 
likely to become a major clinical issue in 
HIV-positive women, because: (i) both HPV 
and HIV viruses are transmitted sexually; 
and (ii) clearance of HPV infection relies 
on functional cell-mediated immunity, 
precisely the immune system attacked by 
HIV infection. There is an urgent need 
for effective strategies for management of 
HPV-associated disease in HIV-positive 
women. This may be achieved through 
extensive public education programmes on 
the prevention and transmission of HPV, 
as well as HIV and HPV vaccination. HPV 
vaccination with the quadrivalent vaccine 
(Gardasil; Merck, USA) has recently been 
shown to significantly reduce the incidence of 
genital warts in individuals less than 21 years 
of age in Australia and New Zealand.[17,18]
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Table 5. (continued) HPV genotypes identified in genital warts
Commonest HPV  
genotypes isolated
HIV-positive
(N=85)
n (%)
HIV-negative
(N=21)
n (%)
Total
(N=106)*
n (%)
35 1 (100.0) - 1
54 1 (100.0) - 1
70 1 (100.0) - 1
82 1 (100.0) - 1
26 - 1 (100.0) 1
*The 3 patients with unknown HIV status are excluded from this table; 2 of them had HPV 11 and 1 HPV 6.
Table 6. Follow-up at 3 months according to HIV and HPV DNA status
HPV DNA
HIV-positive
n (%)
HIV-negative
n (%)
HIV status  
unknown
Total
(N=53)
n (%)
Positive 35/53 (66.0) 13/53 (24.5) - 48 (90.6)
Negative 3/53 (5.7) 2/53 (3.8) - 5 (9.4)
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